Left ventricular mass regression after sutureless implantation of the Perceval S aortic valve bioprosthesis: Preliminary results

Santarpino, G; Pfeiffer, Steffen; Concistrè, Giovanni; Vogt, Ferdinand; Fischlein, T

doi:10.1055/s-0032-1332707

Cited by 5 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no randomized controlled trials. The mean follow-up time was 6 to 8 months for 3 studies (15,18,19), 10 to 16 months for 5 studies (10,11,13,21,22), and 18 to 24 months for 3 studies (12,20,23), as seen in Table 1.…”

Section: Quality Of Evidencementioning

confidence: 97%

See 1 more Smart Citation

Early results of the Sorin® Perceval S sutureless valve: systematic review and meta-analysis

Sian

Selvakumar

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Minimally invasive aortic valve replacement (MAVR) has demonstrated a benefit with respect to increased patient satisfaction due to minimised pain and earlier recovery. Sutureless valves may benefit MAVR and conventional aortic valve replacement (AVR) by reducing operative times and blood transfusion requirements. The Perceval valve (Sorin, Salluggia, Italy) is a self-expanding prosthesis made from bovine pericardium mounted in a nitinol stent, designed to simplify the implantation of an aortic valve. This metaanalysis evaluates the clinical, haemodynamic, and survival outcomes of the Perceval sutureless valve.Methods: An electronic search of 4 databases was performed from January 2000 to December 2016.Primary outcomes included mortality and stroke. Secondary outcomes included minimally invasive access, paravalvular leak, overall long-term survival, postoperative echocardiographic findings, and functional class improvement.Results: After the application of inclusion and exclusion criteria, 14 of 66 relevant articles were selected for assessment. Of these 14 studies, a total number of 2,505 patients were included. The current evidence on the Perceval valve for aortic valve disease is limited to observational studies only. Minimally invasive surgery was performed in 976 patients, of which 336 were via the right anterior thoracotomy approach. The Perceval M and L sutureless valves were the most frequently used, 782 and 770 respectively. The incidence of major adverse events included 30-day mortality (0 to 4.9%), cerebrovascular accident (0 to 3%), permanent pacemaker insertion (0 to 17%), moderate to severe paravalvular leak (0 to 8.6%), and re-operation (0 to 4.8%). Post-operative mean aortic valve gradient ranged from 9 to 15.9 mmHg and post-operative New York Heart Association (NYHA) Class I or II ranged from 82% to 96%. The 1-year survival ranged from 86% to 100%; and 5-year survival was 71.3% to 85.5% in two studies. Conclusions:The Perceval valve is associated with excellent post-operative results in MAVR and in conventional AVR. Larger randomised controlled studies are required to evaluate the long-term efficacy of the prosthesis.

show abstract

Section: Quality Of Evidencementioning

confidence: 97%

“…All 14 studies were observational, which included 7 prospective (11,14,16,(19)(20)(21)(22) and 7 retrospective studies (10,12,13,15,17,18,23). There were no randomized controlled trials.…”

Section: Quality Of Evidencementioning

confidence: 99%

Early results of the Sorin® Perceval S sutureless valve: systematic review and meta-analysis

Sian

Selvakumar

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…They concluded that, at 6 months' follow-up in group 1, the mean LVMI decreased from 185 ± 42. significance. 21 Santarpino and colleagues 18 described a regression, after the implantation of Perceval S sutureless bioprostheses, from 148.4 ± 46 g/m 2 at baseline to 119.7 ± 38.5 g/m 2 at follow-up (mean, 13.5 ± 7.3 mo) (P=0.002). In our experience with the implantation of sutureless 3f Enable aortic bioprostheses, the results at the 6-month follow-up were encouraging: the mean LVMI decreased from 146.1 ± 47.6 g/m 2 at baseline to 118.1 ± 39.8 g/m 2 at follow-up (P=0.003).…”

Section: Discussionmentioning

confidence: 99%

“…9-12 Santarpino and colleagues 18 described LV mass regression at a mean 13.5 ± 7.3 months' follow-up after the implantation of a Perceval S sutureless bioprosthesis (Sorin Group; Saluggia, Italy). However, the impact of the 3f Enable bioprosthesis on LV mass at short-term follow-up has never before been analyzed.…”

Section: Discussionmentioning

confidence: 99%

Regression of Left Ventricular Mass after Implantation of the Sutureless 3f Enable Aortic Bioprosthesis

Concistrè¹,

Miceli²,

Marchi³

et al. 2015

Texas Heart Institute Journal

View full text Add to dashboard Cite

show abstract

“…Sutureless aortic bioprosthesis has been used with promising clinical and hemodynamic performance with relatively shorter surgical times in high-risk patients than conventional valves (4,5) . Although the decrease of echocardiographic parameters related with left ventricular (LV) mass has been reported before, there is not enough study in the literature related with the effect of sutureless prosthesis on LV mass regression (6) .…”

Section: Introductionmentioning

confidence: 99%

Impact of Left Ventricular Mass Index on Early Outcomes After Aortic Valve Replacement with Sutureless Bioprosthetic Valve: A Comparison of Two Decades

Dönmez¹,

Karademir²,

Dedemoğlu³

et al. 2019

Kosuyolu Heart Journal

View full text Add to dashboard Cite

Introduction: The objective of the present study was to elucidate whether high left ventricular mass index (LVMI) affects early outcomes after sutureless bioprosthetic aortic valve replacement (AVR) in aortic stenosis (AS). Patients and Methods: Postoperative early outcomes of 60 high-risk patients with aortic valve stenosis after replacement with sutureless bioprosthetic valve were retrospectively analyzed. Patients were grouped into two depending on LVMI. Left ventricular (LV) mass was calculated using the Devereux formula and indexed to the body surface area. High LVMI was defined as LVMI > 134 g/m 2 for males and LVMI > 100 g/m 2 for females. Early outcomes of surgery were compared between the normal and high LVMI patient groups. Results: Preoperative patient characteristics were similar between the groups. Early mortality was 8.3%. There was no statistically significant difference between the groups with respect to postoperative early complication rates and mortality. LVMI decreased from 114.7 ± 13.7 g/m 2 at baseline to 109 ± 32.2 g/m 2 at follow-up in group I (p= 0.60) and from 192.5 ± 31.9 g/m 2 at baseline to 117.9 ± 25.2 g/m 2 in group II (p< 0.001). Conclusion: The impact of high LVMI on morbidity and mortality after AVR with sutureless bioprosthetic valve was not deleterious in patients with isolated AS. Significant reduction in LVMI at 6 months is encouraging for these high-risk patients with severe LV hypertrophy; however, long-term follow-up is required.

show abstract

Left ventricular mass regression after sutureless implantation of the Perceval S aortic valve bioprosthesis: Preliminary results

Cited by 5 publications

References 12 publications

Early results of the Sorin® Perceval S sutureless valve: systematic review and meta-analysis

Early results of the Sorin® Perceval S sutureless valve: systematic review and meta-analysis

Regression of Left Ventricular Mass after Implantation of the Sutureless 3f Enable Aortic Bioprosthesis

Impact of Left Ventricular Mass Index on Early Outcomes After Aortic Valve Replacement with Sutureless Bioprosthetic Valve: A Comparison of Two Decades

Contact Info

Product

Resources

About